Soluble Fas and Fas-ligand levels in mid-trimester amniotic fluid and their associations with severe small for gestational age fetuses: a prospective observational study

Abstract We aimed to determine the second-trimester amniotic fluid (AF) levels of soluble Fas (sFas) and Fas-ligand (FasL) and investigate their association with fetal growth. Therefore, sFas and FasL levels were measured by enzyme immunoassay in the AF of 21 small for gestational age (SGA), 13 larg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of reproductive immunology 2013-06, Vol.98 (1), p.39-44
Hauptverfasser: Vrachnis, N, Dalainas, I, Papoutsis, D, Samoli, E, Rizos, D, Iliodromiti, Z, Siristatidis, C, Tsikouras, P, Creatsas, G, Botsis, D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 44
container_issue 1
container_start_page 39
container_title Journal of reproductive immunology
container_volume 98
creator Vrachnis, N
Dalainas, I
Papoutsis, D
Samoli, E
Rizos, D
Iliodromiti, Z
Siristatidis, C
Tsikouras, P
Creatsas, G
Botsis, D
description Abstract We aimed to determine the second-trimester amniotic fluid (AF) levels of soluble Fas (sFas) and Fas-ligand (FasL) and investigate their association with fetal growth. Therefore, sFas and FasL levels were measured by enzyme immunoassay in the AF of 21 small for gestational age (SGA), 13 large for gestational age (LGA), and 44 appropriate for gestational age (AGA) fetuses of pregnant women who underwent amniocentesis at between 15 and 22 weeks gestation. Our study results showed that sFas and FasL levels were detectable in AF. sFAS median (25th–75th centile) levels were 3.8 (2.8–4.6) ng/ml in SGA, 3.6 (3.1–4.5) ng/ml in AGA, and 4.0 (3.1–4.4) ng/ml in LGA. FasL median (25th–75th centile) levels were 26.0 (20.3–32.7) pg/ml in SGA, 22.7 (18.4–28.5) pg/ml in AGA, and 21.5 (15.8–30.9) pg/ml in LGA. The differences were not statistically significant. Nevertheless, statistically significant differentiation of FasL levels existed when SGA fetuses in the extremes of distribution (≤5th, ≤2.5th centile) were considered. This is the first study presenting sFas and FasL concentrations in early second-trimester amniotic fluid in AGA, SGA, and LGA fetuses. We found indications that severe and very severe SGA fetuses (≤5th and ≤2.5th centile) have high levels of FasL in the amniotic fluid. This finding probably reflects the increased rate of apoptosis that is assumed to exist in cases of extreme growth restriction.
doi_str_mv 10.1016/j.jri.2013.02.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1353483436</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0165037813000442</els_id><sourcerecordid>1353483436</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-dfdd27d91ba69297fdf0509569beb953be40acd4090dbd1dc73a4317967f81d23</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEotPCA7BBXrJJuLbzCxISqmhBqsSisLYc-2bqwUkGX2fQPBJvidNpWbBgZUv-ztH1OTfLXnEoOPD67a7YBVcI4LIAUQDIJ9mGt43Imxrk02yTmCoH2bRn2TnRDoA30PHn2ZmQVSs4iE32-3b2S--RXWlierLrmXu3Xa8eD-iJuYmNzuYxuBEpYmB6nNwcnWGDX5y9V8U7dOmBaDZORzdPxH65eMcoWQRkNGrv2TAHtk0W94D2TG-RDRgXQnrHNNuHmfZoojsgm3vCcHgEKS72-CJ7NmhP-PLhvMi-X336dvk5v_l6_eXy401uSmhjbgdrRWM73uu6E10z2AEq6Kq667HvKtljCdrYEjqwveXWNFKXkjdd3Qwtt0JeZG9Ovmmen0saV42ODHqvJ5wXUlxWsmxlKeuE8hNq0ugUcFD7FJIOR8VBrQ2pnUoNqbUhBUKlhpLm9YP90o9o_yoeK0nA-xOQsseDw6DIOJwMWhdSOsrO7r_2H_5RG-8mZ7T_gUek3byElGj6haIkULfriqwbwiUAlKWQfwDqxLoq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1353483436</pqid></control><display><type>article</type><title>Soluble Fas and Fas-ligand levels in mid-trimester amniotic fluid and their associations with severe small for gestational age fetuses: a prospective observational study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Vrachnis, N ; Dalainas, I ; Papoutsis, D ; Samoli, E ; Rizos, D ; Iliodromiti, Z ; Siristatidis, C ; Tsikouras, P ; Creatsas, G ; Botsis, D</creator><creatorcontrib>Vrachnis, N ; Dalainas, I ; Papoutsis, D ; Samoli, E ; Rizos, D ; Iliodromiti, Z ; Siristatidis, C ; Tsikouras, P ; Creatsas, G ; Botsis, D</creatorcontrib><description>Abstract We aimed to determine the second-trimester amniotic fluid (AF) levels of soluble Fas (sFas) and Fas-ligand (FasL) and investigate their association with fetal growth. Therefore, sFas and FasL levels were measured by enzyme immunoassay in the AF of 21 small for gestational age (SGA), 13 large for gestational age (LGA), and 44 appropriate for gestational age (AGA) fetuses of pregnant women who underwent amniocentesis at between 15 and 22 weeks gestation. Our study results showed that sFas and FasL levels were detectable in AF. sFAS median (25th–75th centile) levels were 3.8 (2.8–4.6) ng/ml in SGA, 3.6 (3.1–4.5) ng/ml in AGA, and 4.0 (3.1–4.4) ng/ml in LGA. FasL median (25th–75th centile) levels were 26.0 (20.3–32.7) pg/ml in SGA, 22.7 (18.4–28.5) pg/ml in AGA, and 21.5 (15.8–30.9) pg/ml in LGA. The differences were not statistically significant. Nevertheless, statistically significant differentiation of FasL levels existed when SGA fetuses in the extremes of distribution (≤5th, ≤2.5th centile) were considered. This is the first study presenting sFas and FasL concentrations in early second-trimester amniotic fluid in AGA, SGA, and LGA fetuses. We found indications that severe and very severe SGA fetuses (≤5th and ≤2.5th centile) have high levels of FasL in the amniotic fluid. This finding probably reflects the increased rate of apoptosis that is assumed to exist in cases of extreme growth restriction.</description><identifier>ISSN: 0165-0378</identifier><identifier>EISSN: 1872-7603</identifier><identifier>DOI: 10.1016/j.jri.2013.02.003</identifier><identifier>PMID: 23582102</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adult ; Amniotic fluid ; Amniotic Fluid - metabolism ; Apoptosis ; Fas Ligand Protein - metabolism ; fas Receptor - metabolism ; Fas-ligand ; Female ; Fetal Growth Retardation - diagnosis ; Fetal Growth Retardation - immunology ; Fetal Weight ; Fetus ; Gestational Age ; Humans ; Infant, Small for Gestational Age ; Obstetrics and Gynecology ; Pregnancy ; Pregnancy Trimesters ; Prospective Studies ; sFas ; Small for gestational age (SGA)</subject><ispartof>Journal of reproductive immunology, 2013-06, Vol.98 (1), p.39-44</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2013 Elsevier Ireland Ltd</rights><rights>Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-dfdd27d91ba69297fdf0509569beb953be40acd4090dbd1dc73a4317967f81d23</citedby><cites>FETCH-LOGICAL-c408t-dfdd27d91ba69297fdf0509569beb953be40acd4090dbd1dc73a4317967f81d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165037813000442$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23582102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vrachnis, N</creatorcontrib><creatorcontrib>Dalainas, I</creatorcontrib><creatorcontrib>Papoutsis, D</creatorcontrib><creatorcontrib>Samoli, E</creatorcontrib><creatorcontrib>Rizos, D</creatorcontrib><creatorcontrib>Iliodromiti, Z</creatorcontrib><creatorcontrib>Siristatidis, C</creatorcontrib><creatorcontrib>Tsikouras, P</creatorcontrib><creatorcontrib>Creatsas, G</creatorcontrib><creatorcontrib>Botsis, D</creatorcontrib><title>Soluble Fas and Fas-ligand levels in mid-trimester amniotic fluid and their associations with severe small for gestational age fetuses: a prospective observational study</title><title>Journal of reproductive immunology</title><addtitle>J Reprod Immunol</addtitle><description>Abstract We aimed to determine the second-trimester amniotic fluid (AF) levels of soluble Fas (sFas) and Fas-ligand (FasL) and investigate their association with fetal growth. Therefore, sFas and FasL levels were measured by enzyme immunoassay in the AF of 21 small for gestational age (SGA), 13 large for gestational age (LGA), and 44 appropriate for gestational age (AGA) fetuses of pregnant women who underwent amniocentesis at between 15 and 22 weeks gestation. Our study results showed that sFas and FasL levels were detectable in AF. sFAS median (25th–75th centile) levels were 3.8 (2.8–4.6) ng/ml in SGA, 3.6 (3.1–4.5) ng/ml in AGA, and 4.0 (3.1–4.4) ng/ml in LGA. FasL median (25th–75th centile) levels were 26.0 (20.3–32.7) pg/ml in SGA, 22.7 (18.4–28.5) pg/ml in AGA, and 21.5 (15.8–30.9) pg/ml in LGA. The differences were not statistically significant. Nevertheless, statistically significant differentiation of FasL levels existed when SGA fetuses in the extremes of distribution (≤5th, ≤2.5th centile) were considered. This is the first study presenting sFas and FasL concentrations in early second-trimester amniotic fluid in AGA, SGA, and LGA fetuses. We found indications that severe and very severe SGA fetuses (≤5th and ≤2.5th centile) have high levels of FasL in the amniotic fluid. This finding probably reflects the increased rate of apoptosis that is assumed to exist in cases of extreme growth restriction.</description><subject>Adult</subject><subject>Amniotic fluid</subject><subject>Amniotic Fluid - metabolism</subject><subject>Apoptosis</subject><subject>Fas Ligand Protein - metabolism</subject><subject>fas Receptor - metabolism</subject><subject>Fas-ligand</subject><subject>Female</subject><subject>Fetal Growth Retardation - diagnosis</subject><subject>Fetal Growth Retardation - immunology</subject><subject>Fetal Weight</subject><subject>Fetus</subject><subject>Gestational Age</subject><subject>Humans</subject><subject>Infant, Small for Gestational Age</subject><subject>Obstetrics and Gynecology</subject><subject>Pregnancy</subject><subject>Pregnancy Trimesters</subject><subject>Prospective Studies</subject><subject>sFas</subject><subject>Small for gestational age (SGA)</subject><issn>0165-0378</issn><issn>1872-7603</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks1u1DAUhSMEotPCA7BBXrJJuLbzCxISqmhBqsSisLYc-2bqwUkGX2fQPBJvidNpWbBgZUv-ztH1OTfLXnEoOPD67a7YBVcI4LIAUQDIJ9mGt43Imxrk02yTmCoH2bRn2TnRDoA30PHn2ZmQVSs4iE32-3b2S--RXWlierLrmXu3Xa8eD-iJuYmNzuYxuBEpYmB6nNwcnWGDX5y9V8U7dOmBaDZORzdPxH65eMcoWQRkNGrv2TAHtk0W94D2TG-RDRgXQnrHNNuHmfZoojsgm3vCcHgEKS72-CJ7NmhP-PLhvMi-X336dvk5v_l6_eXy401uSmhjbgdrRWM73uu6E10z2AEq6Kq667HvKtljCdrYEjqwveXWNFKXkjdd3Qwtt0JeZG9Ovmmen0saV42ODHqvJ5wXUlxWsmxlKeuE8hNq0ugUcFD7FJIOR8VBrQ2pnUoNqbUhBUKlhpLm9YP90o9o_yoeK0nA-xOQsseDw6DIOJwMWhdSOsrO7r_2H_5RG-8mZ7T_gUek3byElGj6haIkULfriqwbwiUAlKWQfwDqxLoq</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Vrachnis, N</creator><creator>Dalainas, I</creator><creator>Papoutsis, D</creator><creator>Samoli, E</creator><creator>Rizos, D</creator><creator>Iliodromiti, Z</creator><creator>Siristatidis, C</creator><creator>Tsikouras, P</creator><creator>Creatsas, G</creator><creator>Botsis, D</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130601</creationdate><title>Soluble Fas and Fas-ligand levels in mid-trimester amniotic fluid and their associations with severe small for gestational age fetuses: a prospective observational study</title><author>Vrachnis, N ; Dalainas, I ; Papoutsis, D ; Samoli, E ; Rizos, D ; Iliodromiti, Z ; Siristatidis, C ; Tsikouras, P ; Creatsas, G ; Botsis, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-dfdd27d91ba69297fdf0509569beb953be40acd4090dbd1dc73a4317967f81d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Amniotic fluid</topic><topic>Amniotic Fluid - metabolism</topic><topic>Apoptosis</topic><topic>Fas Ligand Protein - metabolism</topic><topic>fas Receptor - metabolism</topic><topic>Fas-ligand</topic><topic>Female</topic><topic>Fetal Growth Retardation - diagnosis</topic><topic>Fetal Growth Retardation - immunology</topic><topic>Fetal Weight</topic><topic>Fetus</topic><topic>Gestational Age</topic><topic>Humans</topic><topic>Infant, Small for Gestational Age</topic><topic>Obstetrics and Gynecology</topic><topic>Pregnancy</topic><topic>Pregnancy Trimesters</topic><topic>Prospective Studies</topic><topic>sFas</topic><topic>Small for gestational age (SGA)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vrachnis, N</creatorcontrib><creatorcontrib>Dalainas, I</creatorcontrib><creatorcontrib>Papoutsis, D</creatorcontrib><creatorcontrib>Samoli, E</creatorcontrib><creatorcontrib>Rizos, D</creatorcontrib><creatorcontrib>Iliodromiti, Z</creatorcontrib><creatorcontrib>Siristatidis, C</creatorcontrib><creatorcontrib>Tsikouras, P</creatorcontrib><creatorcontrib>Creatsas, G</creatorcontrib><creatorcontrib>Botsis, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of reproductive immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vrachnis, N</au><au>Dalainas, I</au><au>Papoutsis, D</au><au>Samoli, E</au><au>Rizos, D</au><au>Iliodromiti, Z</au><au>Siristatidis, C</au><au>Tsikouras, P</au><au>Creatsas, G</au><au>Botsis, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble Fas and Fas-ligand levels in mid-trimester amniotic fluid and their associations with severe small for gestational age fetuses: a prospective observational study</atitle><jtitle>Journal of reproductive immunology</jtitle><addtitle>J Reprod Immunol</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>98</volume><issue>1</issue><spage>39</spage><epage>44</epage><pages>39-44</pages><issn>0165-0378</issn><eissn>1872-7603</eissn><abstract>Abstract We aimed to determine the second-trimester amniotic fluid (AF) levels of soluble Fas (sFas) and Fas-ligand (FasL) and investigate their association with fetal growth. Therefore, sFas and FasL levels were measured by enzyme immunoassay in the AF of 21 small for gestational age (SGA), 13 large for gestational age (LGA), and 44 appropriate for gestational age (AGA) fetuses of pregnant women who underwent amniocentesis at between 15 and 22 weeks gestation. Our study results showed that sFas and FasL levels were detectable in AF. sFAS median (25th–75th centile) levels were 3.8 (2.8–4.6) ng/ml in SGA, 3.6 (3.1–4.5) ng/ml in AGA, and 4.0 (3.1–4.4) ng/ml in LGA. FasL median (25th–75th centile) levels were 26.0 (20.3–32.7) pg/ml in SGA, 22.7 (18.4–28.5) pg/ml in AGA, and 21.5 (15.8–30.9) pg/ml in LGA. The differences were not statistically significant. Nevertheless, statistically significant differentiation of FasL levels existed when SGA fetuses in the extremes of distribution (≤5th, ≤2.5th centile) were considered. This is the first study presenting sFas and FasL concentrations in early second-trimester amniotic fluid in AGA, SGA, and LGA fetuses. We found indications that severe and very severe SGA fetuses (≤5th and ≤2.5th centile) have high levels of FasL in the amniotic fluid. This finding probably reflects the increased rate of apoptosis that is assumed to exist in cases of extreme growth restriction.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>23582102</pmid><doi>10.1016/j.jri.2013.02.003</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0165-0378
ispartof Journal of reproductive immunology, 2013-06, Vol.98 (1), p.39-44
issn 0165-0378
1872-7603
language eng
recordid cdi_proquest_miscellaneous_1353483436
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Amniotic fluid
Amniotic Fluid - metabolism
Apoptosis
Fas Ligand Protein - metabolism
fas Receptor - metabolism
Fas-ligand
Female
Fetal Growth Retardation - diagnosis
Fetal Growth Retardation - immunology
Fetal Weight
Fetus
Gestational Age
Humans
Infant, Small for Gestational Age
Obstetrics and Gynecology
Pregnancy
Pregnancy Trimesters
Prospective Studies
sFas
Small for gestational age (SGA)
title Soluble Fas and Fas-ligand levels in mid-trimester amniotic fluid and their associations with severe small for gestational age fetuses: a prospective observational study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T04%3A26%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20Fas%20and%20Fas-ligand%20levels%20in%20mid-trimester%20amniotic%20fluid%20and%20their%20associations%20with%20severe%20small%20for%20gestational%20age%20fetuses:%20a%20prospective%20observational%20study&rft.jtitle=Journal%20of%20reproductive%20immunology&rft.au=Vrachnis,%20N&rft.date=2013-06-01&rft.volume=98&rft.issue=1&rft.spage=39&rft.epage=44&rft.pages=39-44&rft.issn=0165-0378&rft.eissn=1872-7603&rft_id=info:doi/10.1016/j.jri.2013.02.003&rft_dat=%3Cproquest_cross%3E1353483436%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1353483436&rft_id=info:pmid/23582102&rft_els_id=1_s2_0_S0165037813000442&rfr_iscdi=true